PARMAX
New to Zerodha? Sign-up for free.
New to Zerodha? Sign-up for free.
-
Share Price
-
Financials
-
Revenue mix
-
Shareholdings
-
Peers
-
Forensics
- 5D
- 1M
- 6M
- YTD
- 1Y
- 5Y
- MAX
This data is currently unavailable for this company.
-
Summary
-
Profit & Loss
-
Balance sheet
-
Cashflow
This data is currently unavailable for this company.
(In Cr.) |
---|
(In Cr.) | ||||
---|---|---|---|---|
This data is currently unavailable for this company. |
(In %) |
---|
(In Cr.) |
---|
Financial Year (In Cr.) |
---|
-
Product wise
-
Location wise
Revenue Mix
This data is currently unavailable for this company.
Revenue Mix
This data is currently unavailable for this company.
Recent events
-
News
-
Corporate Actions
Parmax Pharma Updates On Fire Incident At Plant
Dec 13 (Reuters) - Parmax Pharma Ltd PARA.BO:
UPDATE ON FIRE INCIDENT AT PLANT
COMPANY MANAGEMENT ASCERTAINING QUANTUM OF DAMAGE CAUSED
DAMAGE IS COVERED BY INSURANCE ADEQUATELY
Further company coverage: PARA.BO
(([email protected];))
Dec 13 (Reuters) - Parmax Pharma Ltd PARA.BO:
UPDATE ON FIRE INCIDENT AT PLANT
COMPANY MANAGEMENT ASCERTAINING QUANTUM OF DAMAGE CAUSED
DAMAGE IS COVERED BY INSURANCE ADEQUATELY
Further company coverage: PARA.BO
(([email protected];))
Parmax Pharma Reports Fire Incident At Plant
Dec 8 (Reuters) - Parmax Pharma Ltd PARA.BO:
FIRE INCIDENT AT PLANT
FIRE WAS SUCCESSFULLY CONTROLLED IMMEDIATELY
IN PROCESS OF ASCERTAINING ACTUAL LOSS CAUSED BY FIRE
THERE HAS BEEN NO LOSS OR INJURY TO HUMAN LIFE
TAKING ADEQUATE STEPS TO ENSURE RE-FUNCTIONING OF PLANT
Source text for Eikon: ID:nBSEbVctym
Further company coverage: PARA.BO
(([email protected];))
Dec 8 (Reuters) - Parmax Pharma Ltd PARA.BO:
FIRE INCIDENT AT PLANT
FIRE WAS SUCCESSFULLY CONTROLLED IMMEDIATELY
IN PROCESS OF ASCERTAINING ACTUAL LOSS CAUSED BY FIRE
THERE HAS BEEN NO LOSS OR INJURY TO HUMAN LIFE
TAKING ADEQUATE STEPS TO ENSURE RE-FUNCTIONING OF PLANT
Source text for Eikon: ID:nBSEbVctym
Further company coverage: PARA.BO
(([email protected];))
ADVISORY-Incorrect alert on Parmax Pharma withdrawn
June 15 (Reuters) - An alert on HarperCollins Publishers and KKR among the bidders for Simon & Schuster was incorrectly tagged to Parmax Pharma Ltd PARA.BO, an unrelated company. The alert has been withdrawn.
For the correct alert, click here
STORY_NUMBER:FWN38726G
STORY_DATE:15/06/2023
STORY_TIME:[07:32:33]
(([email protected];))
June 15 (Reuters) - An alert on HarperCollins Publishers and KKR among the bidders for Simon & Schuster was incorrectly tagged to Parmax Pharma Ltd PARA.BO, an unrelated company. The alert has been withdrawn.
For the correct alert, click here
STORY_NUMBER:FWN38726G
STORY_DATE:15/06/2023
STORY_TIME:[07:32:33]
(([email protected];))
Events:
More Micro Cap Ideas
See similar 'Micro' cap companies with recent activity
Promoter Buying
Companies where the promoters are bullish
Capex
Companies investing on expansion
Superstar Investor
Companies where well known investors have invested
Popular questions
-
Business
-
Financials
-
Share Price
-
Shareholdings
What does Parmax Pharma do?
Parmax Pharma Limited excels in producing active pharmaceutical ingredients (API) and providing Contract Manufacturing Operations (CMO) with a strong emphasis on quality by design methods in compliance with cGMP standards.
Who are the competitors of Parmax Pharma?
Parmax Pharma major competitors are Saroja Pharma Ind, Colinz Laboratories, Link Pharma Chem, Venmax Drugs&Pharma, Emmessar Biotech&Nut, Unjha Formulations, Desh Rakshak Aushdh. Market Cap of Parmax Pharma is ₹14 Crs. While the median market cap of its peers are ₹15 Crs.
Is Parmax Pharma financially stable compared to its competitors?
Parmax Pharma seems to be less financially stable compared to its competitors. Altman Z score of Parmax Pharma is -0.49 and is ranked 7 out of its 8 competitors.
Does Parmax Pharma pay decent dividends?
The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. Parmax Pharma latest dividend payout ratio is 0% and 3yr average dividend payout ratio is 0%
How has Parmax Pharma allocated its funds?
Companies resources are majorly tied in miscellaneous assets
How strong is Parmax Pharma balance sheet?
Parmax Pharma balance sheet is weak and might have solvency issues
Is the profitablity of Parmax Pharma improving?
The profit is oscillating. The profit of Parmax Pharma is -₹2.09 Crs for TTM, -₹5.78 Crs for Mar 2024 and -₹0.1 Crs for Mar 2023.
Is the debt of Parmax Pharma increasing or decreasing?
Yes, The net debt of Parmax Pharma is increasing. Latest net debt of Parmax Pharma is ₹7.61 Crs as of Mar-25. This is greater than Mar-24 when it was ₹5.81 Crs.
Is Parmax Pharma stock expensive?
Parmax Pharma is expensive when considering the EV/EBIDTA, however latest PE is < 3 yr avg PE. Latest PE of Parmax Pharma is -6.83, while 3 year average PE is 28.66. Also latest EV/EBITDA of Parmax Pharma is 84.75 while 3yr average is 60.16.
Has the share price of Parmax Pharma grown faster than its competition?
Parmax Pharma has given better returns compared to its competitors. Parmax Pharma has grown at ~22.24% over the last 1yrs while peers have grown at a median rate of 1.72%
Is the promoter bullish about Parmax Pharma?
Promoters stake in the company seems stable, and we need to go through filings and allocation of resources to gauge promoter bullishness. Latest quarter promoter holding in Parmax Pharma is 30.8% and last quarter promoter holding is 30.8%.
Are mutual funds buying/selling Parmax Pharma?
There is Insufficient data to gauge this.